Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rykindo
- Development stage
- Approved
- Lead developer
- Luye Pharma
- Modality
- Small Molecules
- Administration
- Intramuscular
01
Overview
Rykindo (LY03004) is an extended-release microsphere formulation of the atypical antipsychotic risperidone, developed by Luye Pharma Group. It is administered via intramuscular injection every two weeks. The drug utilizes a proprietary microsphere technology platform to provide sustained release of risperidone, which acts as an antagonist at dopamine D2 and serotonin 5-HT2A receptors. It is indicated for the treatment of schizophrenia in adults and as maintenance treatment for bipolar I disorder, either as monotherapy or adjunctive therapy to lithium or valproate. Rykindo is notable as the first innovative formulation from a Chinese pharmaceutical company to receive FDA approval.
- Brand names
- Rykindo
- Other names
- risperidone microspheresrisperidone extended-release injectable suspension
02
Targets
ADRA1A (α1A)ADRA2A (α2A)DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)DRD4 (Dopamine D4 Receptor)HRH1 (Histamine H1 Receptor)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)
Beyond the preview
Go deeper on Rykindo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rykindo.